Update on male hormonal contraception

Despite increases in female contraceptive options, 40–45% of pregnancies across the world are still unplanned. While several effective female contraceptive methods have been developed, contraceptive choices for men are still limited to the male condom with its high failure rates and to vasectomies,...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Endocrinology and Metabolism 2019, Vol.10, p.2042018819834846-2042018819834846
Main Authors: Gava, Giulia, Meriggiola, Maria Cristina
Format: Article
Language:English
Subjects:
Birth control
Commercialization
Contraception
Contraceptives
Failure rates
Family planning
Men
Review
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3
cites cdi_FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3
container_end_page 2042018819834846
container_issue
container_start_page 2042018819834846
container_title Therapeutic Advances in Endocrinology and Metabolism
container_volume 10
creator Gava, Giulia
Meriggiola, Maria Cristina
description Despite increases in female contraceptive options, 40–45% of pregnancies across the world are still unplanned. While several effective female contraceptive methods have been developed, contraceptive choices for men are still limited to the male condom with its high failure rates and to vasectomies, which are invasive and not reliably reversible. Several studies have demonstrated a great interest among men and women for effective, reversible, and safe male contraceptive methods. Over the years, numerous studies have been performed to develop male hormonal and nonhormonal safe and effective contraceptives. A variety of new molecules are under development as oral or transdermal hormonal contraceptives for men demonstrating few side effects. In our overpopulated world, the development and commercialization of a male contraceptive method that will allow both men and women to take an active role in family planning is mandatory and further research on this topic is required.
doi_str_mv 10.1177/2042018819834846
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bf2323661bdd4763a254209bdedcadf9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_2042018819834846</sage_id><doaj_id>oai_doaj_org_article_bf2323661bdd4763a254209bdedcadf9</doaj_id><sourcerecordid>2331603473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3</originalsourceid><addsrcrecordid>eNp1kc1LwzAUwIMobszdPUlBBC_VfDVJL4IMv2DgxZ1DmqRbR9vMpBP8783snG5gLgnv_fJL3nsAnCN4gxDntxhSDJEQKBeECsqOwHATSiHK2fHuLMQAjENYwrgoI4SyUzAgUOQ5pWIIrmYrozqbuDZpVG2ThfONa1WdaNd2Xmm76irXnoGTUtXBjrf7CMweH94mz-n09ellcj9NdYZFlxqrraFFwSGmvLRKwEIYzBRjBRecW8Z1qRXiUJQ85jjmiFCIIqRzwbUhI_DSe41TS7nyVaP8p3Sqkt8B5-dS-a7StZVFiQkmjKHCGMoZUTiL7cgLY41Wpsyj6653rdZFE4N2U0-9J93PtNVCzt2HZBTlOONRcL0VePe-tqGTTRW0rWvVWrcOEsc-Z7EADCN6eYAu3drHNkaKEMQgoZxECvaU9i4Eb8vdZxCUm5HKw5HGKxd_i9hd-BlgBNIeCGpuf1_9V_gFuhSnOA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331603473</pqid></control><display><type>article</type><title>Update on male hormonal contraception</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>SAGE Open Access</source><source>PubMed Central</source><creator>Gava, Giulia ; Meriggiola, Maria Cristina</creator><creatorcontrib>Gava, Giulia ; Meriggiola, Maria Cristina</creatorcontrib><description>Despite increases in female contraceptive options, 40–45% of pregnancies across the world are still unplanned. While several effective female contraceptive methods have been developed, contraceptive choices for men are still limited to the male condom with its high failure rates and to vasectomies, which are invasive and not reliably reversible. Several studies have demonstrated a great interest among men and women for effective, reversible, and safe male contraceptive methods. Over the years, numerous studies have been performed to develop male hormonal and nonhormonal safe and effective contraceptives. A variety of new molecules are under development as oral or transdermal hormonal contraceptives for men demonstrating few side effects. In our overpopulated world, the development and commercialization of a male contraceptive method that will allow both men and women to take an active role in family planning is mandatory and further research on this topic is required.</description><identifier>ISSN: 2042-0188</identifier><identifier>EISSN: 2042-0196</identifier><identifier>DOI: 10.1177/2042018819834846</identifier><identifier>PMID: 30899448</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Birth control ; Commercialization ; Contraception ; Contraceptives ; Failure rates ; Family planning ; Men ; Review ; Side effects</subject><ispartof>Therapeutic Advances in Endocrinology and Metabolism, 2019, Vol.10, p.2042018819834846-2042018819834846</ispartof><rights>The Author(s), 2019</rights><rights>The Author(s), 2019. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://www.creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), 2019 2019 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3</citedby><cites>FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3</cites><orcidid>0000-0001-9232-312X ; 0000-0003-0061-9834</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419257/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2331603473?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,4024,4054,21966,25753,27853,27922,27923,27924,27925,37012,37013,44590,44945,45333,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30899448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gava, Giulia</creatorcontrib><creatorcontrib>Meriggiola, Maria Cristina</creatorcontrib><title>Update on male hormonal contraception</title><title>Therapeutic Advances in Endocrinology and Metabolism</title><addtitle>Ther Adv Endocrinol Metab</addtitle><description>Despite increases in female contraceptive options, 40–45% of pregnancies across the world are still unplanned. While several effective female contraceptive methods have been developed, contraceptive choices for men are still limited to the male condom with its high failure rates and to vasectomies, which are invasive and not reliably reversible. Several studies have demonstrated a great interest among men and women for effective, reversible, and safe male contraceptive methods. Over the years, numerous studies have been performed to develop male hormonal and nonhormonal safe and effective contraceptives. A variety of new molecules are under development as oral or transdermal hormonal contraceptives for men demonstrating few side effects. In our overpopulated world, the development and commercialization of a male contraceptive method that will allow both men and women to take an active role in family planning is mandatory and further research on this topic is required.</description><subject>Birth control</subject><subject>Commercialization</subject><subject>Contraception</subject><subject>Contraceptives</subject><subject>Failure rates</subject><subject>Family planning</subject><subject>Men</subject><subject>Review</subject><subject>Side effects</subject><issn>2042-0188</issn><issn>2042-0196</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kc1LwzAUwIMobszdPUlBBC_VfDVJL4IMv2DgxZ1DmqRbR9vMpBP8783snG5gLgnv_fJL3nsAnCN4gxDntxhSDJEQKBeECsqOwHATSiHK2fHuLMQAjENYwrgoI4SyUzAgUOQ5pWIIrmYrozqbuDZpVG2ThfONa1WdaNd2Xmm76irXnoGTUtXBjrf7CMweH94mz-n09ellcj9NdYZFlxqrraFFwSGmvLRKwEIYzBRjBRecW8Z1qRXiUJQ85jjmiFCIIqRzwbUhI_DSe41TS7nyVaP8p3Sqkt8B5-dS-a7StZVFiQkmjKHCGMoZUTiL7cgLY41Wpsyj6653rdZFE4N2U0-9J93PtNVCzt2HZBTlOONRcL0VePe-tqGTTRW0rWvVWrcOEsc-Z7EADCN6eYAu3drHNkaKEMQgoZxECvaU9i4Eb8vdZxCUm5HKw5HGKxd_i9hd-BlgBNIeCGpuf1_9V_gFuhSnOA</recordid><startdate>2019</startdate><enddate>2019</enddate><creator>Gava, Giulia</creator><creator>Meriggiola, Maria Cristina</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9232-312X</orcidid><orcidid>https://orcid.org/0000-0003-0061-9834</orcidid></search><sort><creationdate>2019</creationdate><title>Update on male hormonal contraception</title><author>Gava, Giulia ; Meriggiola, Maria Cristina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Birth control</topic><topic>Commercialization</topic><topic>Contraception</topic><topic>Contraceptives</topic><topic>Failure rates</topic><topic>Family planning</topic><topic>Men</topic><topic>Review</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gava, Giulia</creatorcontrib><creatorcontrib>Meriggiola, Maria Cristina</creatorcontrib><collection>SAGE Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Therapeutic Advances in Endocrinology and Metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gava, Giulia</au><au>Meriggiola, Maria Cristina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on male hormonal contraception</atitle><jtitle>Therapeutic Advances in Endocrinology and Metabolism</jtitle><addtitle>Ther Adv Endocrinol Metab</addtitle><date>2019</date><risdate>2019</risdate><volume>10</volume><spage>2042018819834846</spage><epage>2042018819834846</epage><pages>2042018819834846-2042018819834846</pages><issn>2042-0188</issn><eissn>2042-0196</eissn><abstract>Despite increases in female contraceptive options, 40–45% of pregnancies across the world are still unplanned. While several effective female contraceptive methods have been developed, contraceptive choices for men are still limited to the male condom with its high failure rates and to vasectomies, which are invasive and not reliably reversible. Several studies have demonstrated a great interest among men and women for effective, reversible, and safe male contraceptive methods. Over the years, numerous studies have been performed to develop male hormonal and nonhormonal safe and effective contraceptives. A variety of new molecules are under development as oral or transdermal hormonal contraceptives for men demonstrating few side effects. In our overpopulated world, the development and commercialization of a male contraceptive method that will allow both men and women to take an active role in family planning is mandatory and further research on this topic is required.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>30899448</pmid><doi>10.1177/2042018819834846</doi><orcidid>https://orcid.org/0000-0001-9232-312X</orcidid><orcidid>https://orcid.org/0000-0003-0061-9834</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2042-0188
ispartof Therapeutic Advances in Endocrinology and Metabolism, 2019, Vol.10, p.2042018819834846-2042018819834846
issn 2042-0188
2042-0196
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_bf2323661bdd4763a254209bdedcadf9
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); SAGE Open Access; PubMed Central
subjects Birth control
Commercialization
Contraception
Contraceptives
Failure rates
Family planning
Men
Review
Side effects
title Update on male hormonal contraception
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A39%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20male%20hormonal%20contraception&rft.jtitle=Therapeutic%20Advances%20in%20Endocrinology%20and%20Metabolism&rft.au=Gava,%20Giulia&rft.date=2019&rft.volume=10&rft.spage=2042018819834846&rft.epage=2042018819834846&rft.pages=2042018819834846-2042018819834846&rft.issn=2042-0188&rft.eissn=2042-0196&rft_id=info:doi/10.1177/2042018819834846&rft_dat=%3Cproquest_doaj_%3E2331603473%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c528t-deced4bb70247fea80b8d26a66b7877e67cfca1708f780b72713401b8dc987cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2331603473&rft_id=info:pmid/30899448&rft_sage_id=10.1177_2042018819834846&rfr_iscdi=true